Trial
NCT04262375
A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University Health Network, Toronto
Collaborators
AstraZeneca
Condition
Non Small Cell Lung Cancer
Intervention
Durvalumab
Why stopped
Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does not support further evaluation of this doublet.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-11-17